Aeglea BioTherapeutics Doses First Patient in Phase 3 Trial of Pegzilarginase in Arginase 1 Deficiency
Gilead Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Once-Daily Descovy
ARCA Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting With FDA on Gencaro Development for Atrial Fibrillation
Pharmaceutical Investing Corbus Pharmaceuticals to Commence Phase 3 Study of Lenabasum for the Treatment of Rare Autoimmune Disease Dermatomyositis
Heritage Mining Ltd. Announces Closing of the Second and Final Tranche of its Non-Brokered Private Placement of Units and Flow-Through Units
